4q3u

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 8: Line 8:
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4q3u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4q3u OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4q3u RCSB], [http://www.ebi.ac.uk/pdbsum/4q3u PDBsum]</span></td></tr>
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4q3u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4q3u OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4q3u RCSB], [http://www.ebi.ac.uk/pdbsum/4q3u PDBsum]</span></td></tr>
<table>
<table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The X-ray crystal structure of arginase from Schistosoma mansoni (SmARG) and the structures of its complexes with several amino acid inhibitors have been determined at atomic resolution. SmARG is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to form l-ornithine and urea, and this enzyme is upregulated in all forms of the parasite that interact with the human host. Current hypotheses suggest that parasitic arginases could play a role in host immune evasion by depleting pools of substrate l-arginine that would otherwise be utilized for NO biosynthesis and NO-dependent processes in the immune response. Although the amino acid sequence of SmARG is only 42% identical with that of human arginase I, residues important for substrate binding and catalysis are strictly conserved. In general, classical amino acid inhibitors such as 2(S)-amino-6-boronohexanoic acid (ABH) tend to bind more weakly to SmARG than to human arginase I despite identical inhibitor binding modes in each enzyme active site. The identification of a patch on the enzyme surface capable of accommodating the additional Calpha substitutent of an alpha,alpha-disubstituted amino acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The structures of SmARG complexed with two different alpha,alpha-disubstituted derivatives of ABH are presented and provide a proof of concept for this approach in the enhancement of enzyme-inhibitor affinity.
 +
 +
Crystal Structure of Schistosoma mansoni Arginase, a Potential Drug Target for the Treatment of Schistosomiasis.,Hai Y, Edwards JE, Van Zandt MC, Hoffmann KF, Christianson DW Biochemistry. 2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519. Epub 2014 Jul, 9. PMID:25007099<ref>PMID:25007099</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>

Revision as of 06:34, 23 July 2014

Crystal structure of Schistosoma mansoni arginase in complex with inhibitor nor-NOHA

4q3u, resolution 2.50Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Views
Personal tools
Navigation
Toolbox